Press "Enter" to skip to content

Prostate cancer agent evaluated by PSA progression status – Urology Times

admin 0

Prostate cancer agent evaluated by PSA progression status  Urology Times

A significant proportion of men who progress radiologically while on the androgen receptor inhibitor enzalutamide (XTANDI) do not meet standard criteria for …

“prostate cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *